Statistical Robustness and Follow-up Completeness of Survival Outcomes in Phase III Breast Cancer Trials
Background Breast cancer is the most common malignancy worldwide.
Background Breast cancer is the most common malignancy worldwide. Survival outcomes from phase III RCTs guide approvals, guidelines, and treatment strategies, making statistical stability important. HRs, CIs, and P values show statistical significance but do not directly quantify robu...
Survival outcomes from phase III RCTs guide approvals, guidelines, and treatment strategies, making statistical stability important.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC